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Even with current promising antitumor antibodies, their antitumor effects on
stroma-rich solid cancers have been insufficient. We used mild hyperthermia with
the intent of improving drug delivery by breaking the stromal barrier. Here, we
provide preclinical evidence of cetuximab + mild hyperthermia therapy. We used
four in vivo pancreatic cancer xenograft mouse models with different stroma
amounts (scarce, MIAPaCa-2; moderate, BxPC-3; and abundant, Capan-1 and Ope-
xeno). Cetuximab (1 mg ⁄ kg) was given systemically, and the mouse leg tumors
were concurrently heated using a water bath method for 30 min at three differ-
ent temperatures, 25°C (control), 37°C (intra-abdominal organ level), or 41°C (mild
hyperthermia) (n = 4, each group). The evaluated variables were the antitumor
effects, represented by tumor volume, and in vivo cetuximab accumulation, indi-
rectly quantified by the immunohistochemical fluorescence intensity value ⁄ cell
using antibodies against human IgG Fc. At 25°C, the antitumor effects were suffi-
cient, with a cetuximab accumulation value (florescence intensity ⁄ cell) of 1632, in
the MIAPaCa-2 model, moderate (1063) in the BxPC-3 model, and negative in the
Capan-1 and Ope-xeno models (760, 461). By applying 37°C or 41°C heat, antitu-
mor effects were enhanced shown in decreased tumor volumes. These enhanced
effects were accompanied by boosted cetuximab accumulation, which increased
by 2.8-fold (2980, 3015) in the BxPC-3 model, 2.5- or 4.8-fold (1881, 3615) in the
Capan-1 model, and 3.2- or 4.2-fold (1469, 1922) in the Ope-xeno model, respec-
tively. Cetuximab was effective in treating even stroma-rich and k-ras mutant
pancreatic cancer mouse models when the drug delivery was improved by combi-
nation with mild hyperthermia.
P ancreatic cancer is still refractory to treatment, with a5-year survival rate of 5–7%.(1,2) This limited treatment
efficacy may be attributable to histological features, such as
hypovascularity,(3) and the production of abundant interstitial
stroma that surrounds the cancer cells, which is referred to as
a desmoplastic reaction.(4) As a result, few chemotherapeutic
drugs enter the cancer nodule. Moreover, only a very small
proportion of the drug actually reaches the cancer cells
because the subsequent diffusion is hampered by the thick
interstitial stroma.
Heat has been used to eradicate cancers since the time of
Hippocrates (460–370 BC). A subcategory of hyperthermia,
referred to as mild hyperthermia, has been in use since the
1970s. Mild hyperthermia involves using a temperature of 41–
43°C to improve the effect of co-administered anticancer drugs
and radiation.(5) The reasoning behind this approach is that the
application of mild heat increases blood flow and the perme-
ability of tumor blood vessels, thereby increasing drug accu-
mulation in the target tissue.(6,7) In fact, applying mild
hyperthermia in vivo has been reported to increase blood flow
within tumor tissues by up to three-fold and the antitumor
effects of drugs by up to 3.6-fold.(8)
Cetuximab, an epidermal growth factor receptor (EGFR)-tar-
geted antibody, is a promising candidate for clinical applications
in pancreatic cancer patients because EGFR is highly expressed
in pancreatic cancer cells at frequencies of 60–90%.(9) However,
treating pancreatic cancer patients with a combination of gemc-
itabine and cetuximab did not improve patient prognosis com-
pared with treatment with gemcitabine alone Median survival
time (MST) of 5.9–6.3 months,(10) most likely because cetux-
imab was not adequately delivered to the pancreatic cancer cells
following simple i.v. administration.
We therefore reviewed the potential for combining mAb
drug treatment with mild hyperthermia to deliver effective
amounts of cetuximab to matrix-rich pancreatic cancer.
Reports from as early as the 1990s showed enhanced accumu-
lation and an improved antitumor effect when radioim-
munotherapy was used in combination with mild hyperthermia,
although the booster effect still did not yield satisfactory
outcomes.(11,12)
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The goal of this study was to determine whether mild hyper-
thermia could provide a booster effect for cetuximab therapy.
Using a mouse model of s.c. pancreatic cancer, we provide
preclinical evidence that mild hyperthermia enhances cetux-
imab accumulation and reduces tumor size.
Materials and Methods
Four in vivo pancreatic cancer models with different amounts
of stroma. We used three pancreatic cancer cell line-based
xenograft models. The human pancreatic cancer cell lines
MIAPaCa-2 (CRL-1420), BxPC-3 (CRL-1687), and Capan-1
(HTB-79) were purchased from ATCC (Manassas, VA, USA).
The amounts of induced stroma are different between these
cell lines: the stroma is abundant in Capan-1 (++), modest in
BxPC-3 (+), and very scarce in MIAPaCa-2 ().(13) To test a
more stroma-rich model, we also used a patient-derived tumor
fragment transplantation model (Ope-xeno, ++).
The primary generation of Ope-xeno models was established
by inoculating 2 9 2 9 2-mm pieces of surgically resected tis-
sue fragments from human pancreatic cancer patients into the
backs of mice with 100 lL Matrigel (BD Biosciences, Franklin
Lakes, NJ, USA). The use of the Ope-xeno model was approved
by the Ethics Committee of Tsukuba University Hospital (Tsu-
kuba, Japan). When the implanted pieces generated tumors of
1 cm in diameter, they were harvested and cut into 2 9 2 9 2-
mm pieces and transplanted into other mice. When these second
generation tumors grew, they were minced into 2 9 2 9 2-mm
pieces and preserved in a freezer after soaking in cell cryop-
reservation medium (Cell Banker 1; Juji Field, Tokyo, Japan).
The Ope-xeno model in this study was designated the third gen-
eration, which was confirmed to maintain the histology of the
original surgical sample even after the freeze–thaw process and
to provide dense stromal proliferation.(13)
Epidermal growth factor receptor expression was assessed
by immunohistochemistry.(14) The MIAPaCa-2 Cell-xeno
model and the Ope-xeno model showed high levels of EGFR
expression, whereas the BxPC-3 and Capan-1 Cell-xeno mod-
els showed moderate expression levels (Fig. 1).(15)
In vivo hyperthermia model using the water bath method. We
used the water bath method to apply heat to the mouse
tumors.(16) The femoral region of the right hind leg of the
mouse was used as the inoculation site. For water bath heating,
the mice were anesthetized with inhaled isoflurane and posi-
tioned in specially designed holders that allowed the isolated
leg tumor to be placed in the water bath.
Nude mice (8-week-old female, BALB ⁄ cA-nude; CLEA
Japan, Tokyo, Japan) were used for the experiments. We used
100 lL PBS as a buffer for the 5 9 106 cancer cells that were
inoculated in the Cell-xeno models. We prepared human pan-
creatic cancer cells using RPMI-1640 medium (Sigma-Aldrich,
St. Louis, MO, USA) for Capan-1 and BxPC-3 cells and
DMEM (Sigma-Aldrich) for MIAPaCa-2 cells; the media were
supplemented with 10% FBS.
Study 1: tumor growth inhibition by cetuximab and the boos-
ter effect provided by hyperthermia. When the mouse leg tumor
volume reached 70 mm3, 0.1 mg ⁄kg cetuximab (Merck, Darm-
stadt, Germany) in 100 lL normal saline was systemically
administered through the caudal vein.(15,17,18) We used normal
saline as a solution buffer for cetuximab. The tumors were
then warmed in a water bath for 30 min at different tempera-
tures: 25°C, control temperature; 37°C, intra-abdominal organ
level; and 41°C, mild hyperthermia (n = 4, each treatment
group).(6,19) The cetuximab plus heat treatment was given once
every 3 days for a total of 10 applications (Fig. 2).(18) The
control group received a normal saline injection plus heat
(n = 4). The size of each xenograft was determined by mea-
suring the tumor diameter and calculating the tumor volume
(V) using the following formula: V = pab2 ⁄6 where a is the
maximum diameter and b is the minimum diameter.
Study 2: quantification of in vivo accumulation of cetuximab in
cancer cells and effect of hyperthermia. To objectively deter-
mine the amount of hyperthermia-enhanced cetuximab accu-
mulation in vivo in a single cancer cell, we used an
immunofluorescence technique using anti-human IgG antibod-
ies that recognized the Fc portion of cetuximab, which were
visualized using a fluorescence dye. The mice in all four
groups were treated with cetuximab + different temperatures
(25, 37, or 41°C, n = 4 each; i.e., four groups 9 three temper-
atures) using the same protocol described in Study 1 but for
one total session. At 24 h after the treatment, the mice were
killed by cervical dislocation, the tumors were excised, and
cetuximab accumulation was measured (Fig. 2). The excised
tumors were fixed in formalin and sectioned into 2-lm slices,
Fig. 1. Four in vivo pancreatic cancer cell xenograft mouse models with different stroma amounts were used (scarce, MIAPaCa-2; moderate,
BxPC-3; and abundant, Capan-1 and Ope-xeno). The epidermal growth factor receptor (EGFR) expression level is very high in the MIAPaCa-2 Cell-
xeno and Ope-xeno models and is moderate in the BxPC-3 and Capan-1 Cell-xeno models. MT, Masson trichrome.
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and biotin was blocked using a biotin-blocking system (Dako
Japan, Tokyo, Japan). The sections were then incubated with
an HRP-conjugated polyclonal rabbit anti-human IgG antibody
(Dako, Glostrup, Denmark) at a 1:100 dilution for 24 h at 4°C,
followed by incubation with a biotin-conjugated tyramide sig-
nal amplification system (PerkinElmer, Waltham, MA, USA)
at a 1:50 dilution for 10 min at room temperature. The tissues
were then treated with streptavidin-conjugated Alexa Fluor
488 dye (Alexa 488) (Life Technologies, Grand Island, NY,
USA) at a 1:500 dilution for 30 min at room temperature, fol-
lowed by counterstaining with DAPI (Life Technologies).
The single cell fluorescence intensity was quantified using a
digital microscope (BZ-9000; Keyence, Osaka Japan). A total
of 10 sites, ranging from approximately 100 9 100 to
200 9 500 lm2, was selected for each section at 2009 magni-
fication, and the total Alexa 488 intensity was divided by the
number of cancer cell nuclei (Fig. 3). When selecting the 10
sites, the stromal regions were excluded by manually selecting
areas of cancer cells. The cetuximab accumulation per cancer
cell in a section was defined as the median value of the 10
sites. The mean value for four mice was recorded.
Statistical analyses. All of the statistical analyses were car-
ried out using SPSS-II for Windows (IBM, Armonk, NY, USA),
and the data are presented as the mean  SD. The F-test was
used to account for population variance, and Student’s t-test
and the Tukey–Kramer test were used to compare two groups
and multiple groups, respectively. P-values <0.05 were consid-
ered to be statistically significant. The error bars in the figures
represent the SD.
Results
Study 1: tumor growth inhibition by cetuximab and booster
effect provided by hyperthermia. In the MIAPaCa-2 Cell-xeno
model, cetuximab showed effective antitumor activity at 25°C
(Fig. 4a) (●, 123  30 mm3) compared with the Ns + 25°C
group (○, 1462  790 mm3). There was no apparent increase
in the antitumor effect of cetuximab at 37°C (Fig. 4a) (▲,
109  36 mm3; P = 0.25) or 41°C (■, 151  10 mm3;
P = 0.31) at day 50. Hyperthermia alone was not effective, as
the average tumor sizes at 37°C (M, 1612  364 mm3) and
41°C (□, 1657  1218 mm3) did not differ from those of the
25°C group (P = 0.33, 0.41) (Fig. 4a). Similar negative effects
of heat were confirmed in the other three models.
In the BxPC-3 Cell-xeno model, an intermediate antitumor
effect of cetuximab was observed at 25°C (Fig. 4b) (●,
470  244 mm3) compared with the Ns + 25°C group (○,
1059  1076 mm3). This effect was enhanced by combining
cetuximab treatment with hyperthermia, as demonstrated at
37°C (▲, 189  228 mm3) and 41°C (■, 121  310 mm3) at
day 40 (all P < 0.05).
In the Capan-1 Cell-xeno model, no antitumor effect of
cetuximab was observed at 25°C (Fig. 4c) (●,
1070  20 mm3) compared with the Ns + 25°C group (○,
1059  394 mm3). Hyperthermia enhanced the antitumor
effect of cetuximab, as significant suppression of tumor growth
was observed at 37°C (▲, 789  36 mm3) and 41°C (■,
421  14 mm3) compared with the 25°C group at day 40 (all
P < 0.05). Furthermore, 41°C treatment further enhanced the
cetuximab antitumor effect compared with 37°C treatment at
day 40 (P < 0.05).
In the Ope-xeno model, no antitumor effect of cetuximab
was observed at 25°C (●, 778  38 mm3) compared with the
Ns + 25°C group (○, 774  82 mm3). Hyperthermia only
enhanced the antitumor effect of cetuximab at 41°C (■,
565  120 mm3) at day 70 (P < 0.05) (Fig. 4d).
Study 2: quantification of accumulated cetuximab in a cancer
cell and the effect of hyperthermia. The cetuximab accumula-
tion in MIAPaCa-2 cancer cells was sufficiently intense at
25°C (Fig. 5a-i) and did not increase at 37°C or 41°C
(Fig. 5a-ii,a-iii). The intensity value at 25°C (1632  960;
Fig. 5a-iv, white column) was not increased at 37°C
(1921  848, gray column) or 41°C (1949  690, black col-
umn) (P = 0.34 and 0.23, respectively).
Fig. 2. In vivo hyperthermia model. Study 1,
antitumor effects were determined by measuring
tumor volume over time. Study 2, cetuximab
accumulation in tumor cells was quantified by
immunofluorescence.
(a) (b)
Fig. 3. (a) Alexa 488 immunofluorescence staining in the BxPC-3 Cell-xeno pancreatic cancer xenograft mouse model. Only the target regions
of the cancer cell aggregates were counted (indicated by outlining with a dashed line). (b) Manually selected cancer cell areas with an island-
shaped morphology (left), DAPI nuclear staining (middle), and cell counting by digital microscopy (right) in selected cancer cell areas. The sum of
the Alexa 488 fluorescence intensity in cancer cells was divided by the number of cancer cells to indirectly quantify cetuximab accumulation per
cancer cell.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | April 2016 | vol. 107 | no. 4 | 516
Original Article
Hyperthermia boosts cetuximab effect www.wileyonlinelibrary.com/journal/cas
The accumulation in BxPC-3 cancer cells was moderate at
25°C (Fig. 5b-i) and increased at 37 and 41°C (Fig. 5b-ii,b-
iii). The intensity value at 25°C (1063  1260; Fig. 5b-iv,
white column) was increased at 37°C (2980  1438, gray col-
umn) and 41°C (3015  816, black column) (all P < 0.05).
The accumulation in Capan-1 and Ope-xeno cancer cells was
very low at 25°C (Fig. 5c-i,d-i) and increased at 37 and 41°C
(Fig. 5c-ii,c-iii,d-ii,d-iii). The intensity values at 25°C
(760  756, 461  536; Fig. 5c-iv,d-iv, white column) were
increased at 37°C (1881  870, 1469  472, gray column) and
41°C (3615  634, 1922  1740, black column) (all P < 0.05).
Furthermore, in the Capan-1 Cell-xeno model, the intensity
value at 41°C was higher than that at 37°C (P < 0.05).
Discussion
The effects of mild hyperthermia on antibody therapy were
determined in the 1990s for radioimmunotherapy using stroma-
poor colon cancer mouse models.(11,12) Although the effective-
ness of radioimmunotherapy alone has been insufficient, research
in this field advanced very little in the subsequent 20 years. By
combining mild hyperthermia with cetuximab treatment, we
showed drug accumulation in tumors and potent antitumor
effects in an in vivo model of stroma-rich pancreatic cancer.
Optimal cetuximab effects were obtained in the stroma-poor
MIAPaCa-2 Cell-xeno model, which showed complete
remission without the addition of heat treatment (Fig. 4a).
This effect may be attributed to sufficient in vivo
accumulation of cetuximab in the cancer cells, as demon-
strated by the fluorescence intensity value of 1632 ⁄ cell
(Fig. 5a). Because cetuximab treatment without heat (i.e., at
25°C) was sufficient in the MIAPaCa-2 Cell-xeno model, we
confirmed that there was no need for the additive effect of
mild hyperthermia.
Stroma is viewed as a hindrance to drug delivery.(4,20) In
fact, cancer cells are separated from the nearest blood vessels
by prominent stromal fibers, and the distances between cancer
cells and blood vessels are significantly longer in human pan-
creatic cancer (47.4  43.0 lm) and in the Ope-xeno model
(35.3  39.0 lm) than in the stroma-poor cell xenograft mod-
els (3.9  3.1 lm).(13) In addition, the vessel density of
stroma-rich tumors is lower than that of stroma-poor
tumors.(13) In terms of the relationship between tumor stroma
and hyperthermia, we assumed that stroma-rich cancer would
be a better candidate for the booster effect of hyperthermia.
First, we assumed that applying hyperthermia would affect
physiological phenomena in the tumor stroma, which includes
fibroblasts and endothelial cells. In fact, a previous in vitro study
showed that the colony formation of fibroblasts and endothelial
cells, which play fundamental roles in tumor stroma, was maxi-
mally reduced to 17% and 5%, respectively, in response to
hyperthermia.(21) Furthermore, previous in vivo studies reported
that treating tumors with hyperthermia improved tumor vessel
function and increased the pore size of tumor vessels, thus
(a) (b)
(c) (d)
Fig. 4. Tumor growth curves in four in vivo
pancreatic cancer xenograft mouse models with
different stroma amounts treated with cetuximab
at different temperatures. (a) Mean MIAPaCa-2
Cell-xeno volume at day 50 was not significantly
different in the cetuximab (Cmab) + 37°C group (▲,
109  36 mm3) or the 41°C group (■,
151  10 mm3) compared with the 25°C group (●,
123  30 mm3). In the normal saline control
groups, the mean tumor volume was not
significantly different among the four xenograft
models. (b) Mean BxPC-3 Cell-xeno volume at day
40 was significantly smaller in the cetuximab + 37°C
group (▲, 189  228 mm3) and the 41°C group (■,
121  310 mm3) compared with the 25°C group (●,
470  244 mm3). *P < 0.05, Cmab + 37 group and
Cmab + 41 group versus Cmab + 25 group. (c)
Mean Capan-1 Cell-xeno volume at day 40 was
significantly smaller in the cetuximab + 37°C group
(▲, 789  36 mm3) and the 41°C group (■,
421  14 mm3) compared with the 25°C group (●,
1070  20 mm3). Furthermore, the mean tumor
volumes were significantly smaller in the
cetuximab + 41°C group (■, 421  14 mm3)
compared with the 37°C group (▲, 789  36 mm3).
*P < 0.05, Cmab + 37 group and Cmab + 41 group
versus Cmab + 25 group. **P < 0.05, Cmab + 41
group versus Cmab + 37 group. (d) Mean Ope-xeno
volume at day 70 was significantly smaller in the
Cetuximab + 41°C group (■, 565  120 mm3)
compared with the 37°C group (▲, 823  38 mm3)
and the 25°C group (●, 778  38 mm3). *P < 0.05,
Cmab + 41 group versus Cmab + 25 group.
**P < 0.05, Cmab + 41 group versus Cmab + 37
group.
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increasing anticancer drug extravasation.(21,22) These findings
indicated that hyperthermia could improve drug delivery by
reducing the stromal barrier or increasing anticancer drug
extravasation.
Second, we assumed that hyperthermia would improve
drug delivery by increasing tumor blood flow. Stroma-rich
tumors are largely hypovascular; therefore, there is less blood
supply per unit of tumor weight than in stroma-poor and
hypervascular tumors. We assumed that the blood flow
increase after heating compared with before heating would
be more pronounced in stroma-rich cancer. The number of
vessels, the resultant hypoxia, and the low pH of the intratu-
mor environment are recognized hallmarks of stroma-rich
tumors that evoke resistance to anticancer drugs and radia-
tion.(4,20) After application of mild hyperthermia, the oxygen
content and pH of this stroma-rich tumor environment
increase, rendering the tumor more susceptible to anticancer
drugs and radiation.(6–8)
The abundance of the tumor stroma is closely related to the
effect of cetuximab plus mild hyperthermia treatment. The gen-
eral explanation for this phenomenon is that tumors with more
abundant stroma accumulate less cetuximab, and thus, tumor
growth is not inhibited under normal conditions (i.e., at 25°C).
In fact, a moderate antitumor effect was observed in the BxPC-
3 Cell-xeno (moderate stroma) model at 25°C; however, this
effect was weaker than that observed in the stroma-poor MIA-
PaCa-2 Cell-xeno model (Fig. 4b). In the stroma-rich Capan-1
Cell-xeno and Ope-xeno models, we observed no effect at
25°C. With the application of mild heat (37°C), the antitumor
effects increased in the BxPC-3 Cell-xeno model and were sig-
(a)
(b)
(c)
(d)
iv
iv
iv
iv
Fig. 5. Cetuximab accumulation in cancer cells in four in vivo pancreatic cancer xenograft mouse models with different stroma amounts. (a)
MIAPaCa-2 Cell-xeno model. The intensity values in the cetuximab + 25°C group (iv, white column) did not increase further with treatment at
37°C (gray column) or 41°C (black column). (b) BxPC-3 Cell-xeno model. The intensity values were significantly increased in the 37°C (iv, gray col-
umn) and 41°C (black column) groups compared with the cetuximab (Cmab + 25°C group (white column). *P < 0.05. (c) Capan-1 Cell-xeno model.
The intensity values in the 37°C (iv, gray column) and 41°C (black column) groups were significantly increased compared with the cetux-
imab + 25°C group (white column). Furthermore, the Alexa 488 intensity values in the 41°C group (black column) were higher than those in the
cetuximab + 37°C group (gray column). *P < 0.05. **P < 0.05. (d) Ope-xeno model. The intensity values were significantly higher in the 37°C (iv,
gray column) and 41°C (black column) groups compared with the cetuximab + 25°C group (white column). *P < 0.05.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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nificantly increased in the Capan-1 model (Fig. 4b,c). More-
over, when the temperature was increased to 41°C, the tumors
in the BxPC-3 Cell-xeno model were completely eradicated,
the effectiveness of cetuximab in the Capan-1 model increased,
and we detected an effect in the stroma-rich Ope-xeno model
(Fig. 4b–d). Of note, the additive effect of mild hyperthermia
appeared to be more significant in stroma-rich cancers, such as
the Capan-1 Cell-xeno model.
The antitumor booster effect of mild hyperthermia may be
due to increased cetuximab accumulation, as measured by fluo-
rescence intensity values. The baseline accumulation (i.e., at
25°C without heat treatment) of cetuximab was inversely pro-
portional to the amount of stroma present (Fig. 5a-iv–d-iv,
white columns), and the values detected in the moderate to
rich stroma models were far below the benchmark value of
approximately 1600–2000 ⁄ cell in the MIAPaCa-2 Cell-xeno
model. Applying 37°C heat increased these values by 2.8-,
2.5-, and 3.2-fold in the BxPC-3, Capan-1 Cell-xeno and Ope-
xeno models, respectively, achieving values that were compa-
rable to the baseline value in the MIAPaCa-2 Cell-xeno model
of 1600–2000 ⁄ cell. Moreover, in the stroma-rich Capan-1
Cell-xeno model, treatment with 41°C heat resulted in an
increased booster effect of up to 4.8-fold compared with the
baseline value of 760 ⁄ cell at 25°C.
Thus, the question arises as to why applying heat has such a
considerable effect. One explanation is that mild hyperthermia
increases blood flow in the tumor and enhances tumor vessel
permeability, thereby promoting cetuximab delivery to the tar-
get tumor and enhancing the antitumor effect. The mechanisms
underlying the hyperthermia-induced increase in tumor blood
flow and tumor vessel permeability have been previously
reported.(7,23–25) In terms of the heating period, Song et al.
previously reported that the blood flow in mammary adenocar-
cinoma R3230 tumors increased approximately 1.5-fold imme-
diately after heating at 40.5°C or 41.58°C for 30–60 min,
whereas it increased 2.5-fold 24 h after heating at 41.58°C for
60 min.(7,23–25) Therefore, we think that the hyperpermeability
of tumor vasculature is maximally enhanced by mild hyper-
thermia at 24 h after heating.
Tumor blood vessels dilate in response to mildly elevated
temperatures, most likely due to smooth muscle relaxation
through stimulation by nitric oxide synthesized by endothelial
cells.(23) Subsequently, blood enters the dilated arterioles in the
tumor and floods the network of capillary-like tumor blood
vessels, increasing the intravascular pressure and flow rate.(7)
Furthermore, previous in vivo studies have shown that
increased hyperthermia-induced blood flow is caused by vessel
dilation and the recruitment of capillaries following stimulation
with vasoactive compounds such as bradykinin and ⁄or his-
tamine.(24) Regarding the mechanisms underlying hyperther-
mia-enhanced tumor vessel permeability, the efficacy of most
chemotherapeutics is usually predicated on achieving adequate
drug transport across the endothelial layer and into the tumor
interstitial stroma. The gaps within the endothelial lining are
an indication of the stress induced on the tumor vasculature by
mild hyperthermia. In response to thermal stress, the loosening
or creation of gaps between endothelial cells in tumor vessels
improves stromal delivery.(25)
Another possible explanation for the enhanced anticancer
effect of cetuximab combined with mild hyperthermia is an
increase in the antigen–antibody interaction between cetuximab
and EGFR, which is known to be affected by temperature. In
fact, Johnstone et al. assessed the effects of temperature over a
range of 1–37°C and reported a 2- to 18-fold increase in the
association rate and a 20- to 50-fold increase in the dissocia-
tion rate of antibodies to and from murine cell surface anti-
gens, respectively.(26) However, the temperature range used for
mild hyperthermia, that is, heating from a baseline of 37–
45°C, did not affect the association or dissociation rates of the
mAb binding.(27) We now understand that altering the interac-
tion kinetics of mAbs does not play a role in the hyperther-
mia-induced enhancement of mAb targeting to cancer cells.
Tumors that carry k-ras mutations, such as pancreatic can-
cer, are not candidates for anti-EGFR antibody drug ther-
apy.(28–30) However, our data indicate that cetuximab is
effective in pancreatic cancers with the k-ras mutation, such as
the MIAPaCa-2 and Capan-1 cell lines,(30,31) if a sufficient
amount of the antibody can be delivered to and accumulate at
the target site. Moreover, in vivo and in vitro studies that used
EGFR knockdown to suppress the proliferation of a pancreatic
cancer cell line carrying the k-ras mutation and a clinical study
of anti-EGFR antibody drugs in patients with pancreatic cancer
showed no differences in outcome related to k-ras status.(30,32)
Although the majority (>90%) of clinical pancreatic cancers
are positive for k-ras mutation, cetuximab may be effective if
used in combination with mild hyperthermia.
The majority of studies investigating mild hyperthermia have
conventionally been carried out in settings comparing 25 and
41°C, likely because mild hyperthermia is primarily used to
target body surface cancers such as those of the skin or
neck.(5,33) However, if we intend to treat i.p. tumors such as
pancreatic cancer, which occur in a 37°C environment, then
comparisons between heat treatment at 37 and 41°C are indis-
pensable. Because such studies have largely been lacking, the
results of the present study provide valuable data showing that
cetuximab accumulation and the resulting antitumor effects are
enhanced by treatment at 41°C compared with 37°C, especially
in the stroma-rich Capan-1 Cell-xeno and Ope-xeno models.
Fortunately, microwave or radiofrequency energy applicators
for delivering mild hyperthermia, such as the Thermotron RF-
8 (Yamamoto Vinita, Osaka, Japan), can be used clinically to
treat advanced i.p. tumors.(6) Consequently, combining cetux-
imab and mild hyperthermia may be a realistic option to con-
sider for the clinical treatment of pancreatic cancer patients.
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